To explore the clinical efficacy of Banxia Baizhu Tianma Decoction on patients with phlegm turbidity obstruction type of otolithiasis in recovery phase.

A total of 135 patients with otolithiasis of phlegm turbidity obstruction type were selected and classified into control group (otolith manipulative reduction treatment, 68 cases) and treatment group (otolith manipulative reduction treatment plus Banxia Baizhu Tianma Decoction, 67 cases) by random number table method. The number of cumulative occurrences, duration, treatment effective rate, TCM syndromes scores, dizziness handicap inventory (DHI), Hamilton anxiety scale (HAMA) and treatment safety were compared between groups of patients.

The number of cumulative occurrences and duration in the control group were (3.18 ± 0.59) times and (30.51 ± 5.16) d and those in the treatment group were (2.59 ± 0.61) times and (25.69 ± 5.39) d, and the two indexes in the control group were higher than those in the treatment group (t=5.712, 5.308, < 0.001) . The effective rate of treatment in the treatment group with 95. 52% (64/67) was higher than 82.35% (56/68) in the control group (P <0. 05). After treatment, the scores of various TCM syndromes were lower in the treatment group than those in the control group (P <0.05). The scores of items of DHI in the treatment group after treatment were lower than those in the control group (P <0.05). After treatment, the treatment group had lower HAMA scores than the control group (P <0.05). No statistical difference was exhibited in the safety between both groups (P >0.05).

Banxia Baizhu Tianma Decoction for phlegm turbidity obstruction type of otolithiasis in recovery phase can effectively reduce the number and time of recurrence, enhance the effective rate of treatment, improve the symptoms, relieve the vertigo degree, and alleviate the anxiety of patients, and it will not increase the risk of treatment.